Compare JZXN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | INDP |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 4.5M |
| IPO Year | 2020 | 2021 |
| Metric | JZXN | INDP |
|---|---|---|
| Price | $1.04 | $1.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 19.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.27 |
| 52 Week High | $8.50 | $13.24 |
| Indicator | JZXN | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 48.42 |
| Support Level | $0.84 | $1.65 |
| Resistance Level | $1.19 | $2.18 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 31.53 | 48.71 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.